Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study

被引：0
|
作者：
Patricia Pozo-Rosich
Messoud Ashina
Stewart J. Tepper
Sidsel Jensen
Line Pickering Boserup
Mette Krog Josiassen
Bjørn Sperling
机构：
[1] Headache Unit,Neurology Department
[2] Hospital Universitari Vall d’Hebron,Headache Research Group, Department of Medicine
[3] Vall d’Hebron Institute of Research,Department of Neurology, Danish Headache Center
[4] Universitat Autonoma de Barcelona,Department of Clinical Medicine
[5] Copenhagen University Hospital–Rigshospitalet,undefined
[6] University of Copenhagen,undefined
[7] New England Institute for Neurology and Headache,undefined
[8] H. Lundbeck A/S,undefined
来源：
Neurology and Therapy | 2024年 / 13卷
关键词：
Anti-CGRP; Eptinezumab; Migraine; Preventive treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：339 / 353
页数：14
相关论文
共 50 条
  • [21] Efficacy of erenumab in chronic migraine patients with medication overuse and prior preventive treatment failure
    Dodick, D.
    Tepper, S.
    Diener, H. -C.
    Tassorelli, C.
    Lucas, S.
    Evers, S.
    Zhang, F.
    Chou, D.
    Tenenbaum, N.
    Klatt, J.
    Mikol, D.
    Lima, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 811 - 811
  • [22] Eptinezumab Improved Work Productivity in Adults With Migraine and Prior Preventive Treatment Failures: Results From the Randomized, Double-Blind, Placebo-Controlled DELIVER Study
    Goadsby, P.
    Barbanti, P.
    Lambru, G.
    Ettrup, A.
    Christoffersen, C. L.
    Josiassen, K.
    Phul, R.
    Sperling, B.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [23] Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS
    Lipton, R. B.
    Chalermpalanupap, N.
    Tatsuoka, Y.
    Nagy, K.
    Liu, Y.
    Carr, K.
    McAllister, P.
    Nahas, S. J.
    Trugman, J. M.
    Sacco, S.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [24] A Phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Trial
    Lipton, R. B.
    Saper, J.
    Ashina, M.
    Biondi, D.
    Bhattacharya, S.
    Hirman, J.
    Schaeffler, B.
    Cady, R.
    HEADACHE, 2018, 58 : 80 - 80
  • [25] Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses
    Lebwohl, Mark G.
    Armstrong, April W.
    Alexis, Andrew F.
    Lain, Edward L.
    Jacobson, Abby A.
    DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2709 - 2726
  • [26] Optimization of acute treatment and headache-related impact following eptinezumab initiated during a migraine attack: Post hoc analysis of the RELIEF study
    Buse, D. C.
    Lipton, R. B.
    Ettrup, A.
    Josiassen, M.
    Lindsten, A.
    Cady, R.
    HEADACHE, 2022, 62 : 116 - 116
  • [27] Sustained and Subsequent Response to Atogepant Among Individuals With Episodic Migraine With Prior Treatment Failure: Post Hoc Analysis of the ELEVATE Trial
    Sacco, Simona
    Nagy, Krisztian
    Chalermpalanupap, Natty
    Vernieri, Fabrizio
    Smith, Jonathan H.
    Holle-Lee, Dagny
    Liu, Yingyi
    Carr, Karen
    Pozo-Rosich, Patricia
    Lipton, Richard B.
    CEPHALALGIA, 2023, 43 (1supp) : 265 - 266
  • [28] EFFECT OF ERENUMAB ON PATIENT-REPORTED OUTCOMES IN EPISODIC MIGRAINE PATIENTS WITH PRIOR PROPHYLACTIC TREATMENT FAILURE: RESULTS FROM A POST HOC ANALYSIS OF THE STRIVE STUDY
    Pascual, J.
    Buse, D. C.
    Starling, A.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Picard, H.
    Klatt, J.
    Mikol, D. D.
    CEPHALALGIA, 2018, 38 : 47 - 48
  • [29] Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
    Spierings, Egilius L. H.
    Karppa, Mikko
    Ning, Xiaoping
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    Reuter, Uwe
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [30] Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
    Egilius L. H. Spierings
    Mikko Kärppä
    Xiaoping Ning
    Joshua M. Cohen
    Verena Ramirez Campos
    Ronghua Yang
    Uwe Reuter
    The Journal of Headache and Pain, 2021, 22
12345